Install
BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe. VIEW ALL FEATURED COMPANIES VIEW ALL FEATURED COMPANIES VIEW ALL FEATURED COMPANIES V
- 340articles · 30d
- 2+ hour agolatest article
- Aug 17, 2026earliest in window
- 91%with images
- 291avg words
- Economy, Business & Finance 195
- Health & Wellness 159
- Medical 158
- Business & Industrial 142
- Finance & Business 132
- Health 75
- Science & Technology 53
- Science & Nature 34
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Alchemab Therapeutics Expands Leadership Team, Appointing Dr Ben Porter-Brown as CMO to Propel the Clinical Advancement of Its Pipeline
3+ day, 15+ hour ago (429+ words) BioSpace Alchemab Therapeutics Expands Leadership Team, Appointing Dr Ben Porter-Brown as CMO to Propel the Clinical Advancement of Its Pipeline CAMBRIDGE, England--(BUSINESS WIRE)--Clinical-stage biotech Alchemab Therapeutics has appointed experienced pharma and biotech leader Dr Ben Porter-Brown as Chief…...
Definium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026
3+ day, 18+ hour ago (205+ words) Emerge Phase 3 study podium poster to be featured in “Latest Discoveries & Emerging Trends in MDD” session New epidemiological research on risks associated with anxiety and depression plus five posters across clinical program NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium…...
Lotus Neuro Launches to Deliver the Next Generation of Therapies Across the Blood-Brain Barrier
4+ day, 12+ hour ago (216+ words) Through its Proof of Pharmacology (POP) Challenge, launched in June 2026, Lotus Neuro is funding investigators at leading neuroscience institutions to add focused ultrasound study arms to existing investigational drug programs, generating clinical evidence of drug delivery and target engagement in…...
Tenpoint Therapeutics to Participate in Upcoming Investor Conferences and Medical Meetings
4+ day, 12+ hour ago (200+ words) BioSpace Tenpoint Therapeutics to Participate in Upcoming Investor Conferences and Medical Meetings LONDON & WARREN, N.J.--(BUSINESS WIRE)--Tenpoint Therapeutics, Ltd., a global commercial ophthalmic pharmaceutical company focused on developing groundbreaking treatments to improve vision in the aging eye, today announced participation…...
Coya Therapeutics Announces Publication of Preclinical Study Demonstrating Combination Immunomodulatory Effects of COYA 303 in a Well-Established Model of Peripheral and CNS Inflammation
5+ day, 11+ hour ago (96+ words) Study results showed complementary immunomodulatory effects of COYA 303, a combination of proprietary low-dose IL-2 (LD-IL2) and a GLP-1 Receptor Agonist (GLP-1RA), compared to either LD-IL2 or GLP-1RA as monotherapy Coya will continue to pursue non-dilutive avenues and potential partnerships to advance the COYA…...
Stoke Therapeutics to Present at the Cantor Global Healthcare Conference
1+ week, 4+ day ago (290+ words) BioSpace Stoke Therapeutics to Present at the Cantor Global Healthcare Conference BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a…...
Calluna Pharma Announces Participation in Upcoming Scientific and Investor Conferences
1+ week, 5+ day ago (209+ words) Company to highlight Phase 2 AURORA study of CAL101 in IPF ahead of planned Q1 2027 readout European Respiratory Society (ERS) Congress 2026 Barcelona, Spain Sept. 5–9, 2026 Jonas Hallen, M.D., Ph.D. (CMO) and Toby Maher, M.D., Ph.D. (Coordinating Investigator on the AURORA study) will…...
Arrowhead's new Redemplo findings in severe hypertriglyceridemia have analysts split
1+ week, 6+ day ago (412+ words) In the Phase 3 SHASTA-3 and SHASTA-4 trials, total treatment-emergent adverse events (TEAE) were similar between plozasiran and placebo arms, but serious TEAEs only occurred in 8.3% of patients on plozasiran versus 10% on placebo comparators. The detailed safety data were presented Sunday…...
Seaport Therapeutics to Present at Citi’s 2026 Biopharma Back to School Conference and Participate in 21st Annual Wells Fargo Healthcare Conference
1+ week, 6+ day ago (213+ words) BioSpace Seaport Therapeutics to Present at Citi’s 2026 Biopharma Back to School Conference and Participate in 21st Annual Wells Fargo Healthcare Conference BOSTON--(BUSINESS WIRE)--Seaport Therapeutics, Inc. (Nasdaq: SPTX) (“Seaport” or the “Company”), a clinical-stage therapeutics company that is inventing and…...
BMS’ neuro renaissance was built on back of Celgene mega-merger
1+ week, 6+ day ago (831+ words) When it comes to neuroscience, Bristol Myers Squibb watchers are laser-focused on the upcoming readouts for Cobenfy—the schizophrenia drug the pharma acquired in the $14 billion purchase of Karuna Therapeutics—in Alzheimer’s disease psychosis. But BMS has a deeper neuro…...